We investigated whether the combination of VVL-m12 with α-PD1 antibody or the sequential provision of VVL expressing IL-m12 then VV-msPD1 was able to enhance the antitumor efficacy in murine lung cancer. The gene discussed is PDCD1; the disease is lung cancer.